LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Robert N, Somerfield MR, Edgar BJ, Mendelson DS, Richard M, Sharp SA, Smith TJ, James T. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline. J Clin Oncol. 2016;25(12):1596–1605. doi:10.1200/JCO.2006.10.1949.
   Google Scholar
• Fang Y, Wu J, Li T, Luo Y, Qiu Q, Quan X, Gao L, Liu W. Biological effects of novel “combi-targeting” molecule and its effect on DNA repair pathway in hormone-refractory prostate cancer. Am J Cancer Res. 2014;5(8):2387–2395. PMID:26396914.
   Web of Science ®Google Scholar
• Lin E, Chen MC, Huang CY, Hsu SL, Huang WJ, Lin MS, Wu JC, Lin H. All-trans retinoic acid induces DU145 cell cycle arrest through Cdk5 activation. Cell Physiol Biochem. 2014;33(6):1620–1630. doi:10.1159/000358724.
   PubMedGoogle Scholar
• Eisenberger MA. Chemotherapy for endocrine resistant cancer of the prostate. Prog Clin Biol Res. 1990;359:155–164. PMID:2284289.
   PubMedGoogle Scholar
• Lu G, Shuai C, Yuwei W, Akira W, Laura B, Zhen S, Yuzhuo W, Haojie H. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69(21):8386–8394. doi:10.1158/0008-5472.CAN-09-1504.
   PubMed Web of Science ®Google Scholar
• Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 2015;71(S3):1098–1109. doi:10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g.
   Google Scholar
• Armstrong DK, Bundy B, Winzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Gynecologic oncology group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. doi:10.1056/NEJMoa052985.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Felici A, Cognetti F. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358(2):197;author reply 198. doi:10.1056/NEJMc073152.
   PubMedGoogle Scholar
• Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev. 1993;19(4):351–386. doi:10.1016/0305-7372(93)90010-o.
   PubMed Web of Science ®Google Scholar
• Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer. 2011;18(4):R103–123. doi:10.1530/ERC-10-0343.
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159. doi:10.1038/nrg2521.
   PubMed Web of Science ®Google Scholar
• Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol Cancer. 2017;16(1):9. doi:10.1186/s12943-017-0583-1.
   PubMed Web of Science ®Google Scholar
• Hu YR, Yu YC, You S, Li K, Tong X, Chen S, Chen E, Lin XZ, Chen Y. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16(1):174. doi:10.1186/s12943-017-0743-3.
   PubMedGoogle Scholar
• Zeng Z, Bo H, Gong Z, Lian Y, Li X, Li X, Zhang W, Deng H, Zhou M, Peng S, et al. AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumour Biol. 2016;37(1):729–737. doi:10.1007/s13277-015-3860-x
   PubMedGoogle Scholar
• Feng W, Ni H, Feng S, Min L, Lin C. Overexpression of lncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. Biomed Pharmacother. 2016;81:152–159. doi:10.1016/j.biopha.2016.04.009.
   PubMed Web of Science ®Google Scholar
• Hao B, Zhaojian G, Wenling Z, Xiayu L, Yong Z, Qianjin L, Pan C, Lei S, Yu L, Yizhou J. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015;6(24):20404–20418. doi:10.18632/oncotarget.4057.
   PubMedGoogle Scholar
• Yang ZT, An F, Hu JD, Zhao WH. Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression. Eur Rev Med Pharmacol Sci. 2019;23(8):3284–3290. doi:10.26355/eurrev_201904_17690.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Xiu C, Song K, Pei R, Miao S, Mao X, Sun J, Jia S. Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance. J Cell Mol Med. 2018;22(9):4253–4262. doi:10.1111/jcmm.13707.
   PubMed Web of Science ®Google Scholar
• Jovanovic M, Hengartner MO. miRNAs and apoptosis: rNAs to die for. Oncogene. 2006;25(46):6176–6187. doi:10.1038/sj.onc.1209912.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H. MicroRNA signatures in human ovarian cancer. Cancer Res. 2009;67(18):8699–8707. doi:10.1158/0008-5472.CAN-07-1936.
   Web of Science ®Google Scholar
• Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2010;120(5):1046–1054. doi:10.1002/ijc.22394.
   Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Tapio V. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130–6135. doi:10.1158/0008-5472.CAN-07-0533.
   PubMed Web of Science ®Google Scholar
• Wang T, Ren Y, Liu R, Ma J, Shi Y, Zhang L, Bu R. miR-195-5p suppresses the proliferation, migration, and invasion of oral squamous cell carcinoma by targeting TRIM14. Biomed Res Int. 2017;7378148. doi:10.1155/2017/7378148.
   PubMed Web of Science ®Google Scholar
• Chang M, Lin H, Fu H, Wang B, Han G, Fan M. MicroRNA‐195‐5p regulates osteogenic differentiation of periodontal ligament cells under mechanical loading. J Cell Physiol. 2017;232(12):3762–3774. doi:10.1002/jcp.25856.
   PubMed Web of Science ®Google Scholar
• Liu R, Liu X, Zheng Y, Jie GU, Xiong S, Jiang P, Jiang X, Huang E, Yang Y, Di GE. MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett. 2014;8(5):2193–2200. doi:10.3892/ol.2014.2500.
   PubMed Web of Science ®Google Scholar
• Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 2015;4(5):745–758. doi:10.1002/cam4.409.
   PubMed Web of Science ®Google Scholar
• Liu F, Hu L, Pei Y, Zheng K, Wang W, Li S, Qiu E, Shang G. Zhang J and Zhang X. Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis. BMC Cancer. 2020;20(1):258. doi:10.1186/s12885-020-6665-2.
   PubMed Web of Science ®Google Scholar
• Cai C, He H, Duan X, Wu W, Mai Z, Zhang T, Fan J, Deng T, Zhong W, Liu Y, et al. miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression. Oncol Rep. 2018;39(4):1658–1670. doi:10.3892/or.2018.6240
   PubMed Web of Science ®Google Scholar
• Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y, Liu Y, Li S, Liang Z, Xu X, et al. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. J Transl Med. 2015;13(1):289. doi:10.1186/s12967-015-0650-6
   PubMedGoogle Scholar
• Ge D, Han L, Huang S, Peng N, Wang P, Jiang Z, Zhao J, Su L, Zhang S, Zhang Y, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014;10(6):957–971. doi:10.4161/auto.28363
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang D, Lv J, Wang S, LncRNA ZQ. SNHG15 acts as an oncogene in prostate cancer by regulating miR-338-3p/FKBP1A axis. Gene. 2019;705:44–50. doi:10.1016/j.gene.2019.04.033.
   PubMed Web of Science ®Google Scholar
• McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O’Donovan N, Stordal B. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol. 2014;4:40. doi:10.3389/fonc.2014.00040.
   PubMedGoogle Scholar
• Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Databaseissue):D92–97. doi:10.1093/nar/gkt1248.
   PubMed Web of Science ®Google Scholar
• Cai Q, Wang S, Jin L, Weng M, Zhou D, Wang J, Tang Z, Quan Z. Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Mol Cancer. 2019;18(1):82. doi:10.1186/s12943-019-1016-0.
   PubMed Web of Science ®Google Scholar